West Paces Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $6.27K | Hold |
12
| – | – | ﹤0.01% | 436 |
|
|
2026
Q2 | $5.96K | Buy |
+12
| New | +$5.32K | ﹤0.01% | 435 |
|
|
2025
Q2 | – | Sell |
-7
| Closed | -$3.39K | – | 549 |
|
|
2025
Q1 | $3.39K | Hold |
7
| – | – | ﹤0.01% | 402 |
|
|
2024
Q4 | $2.82K | Hold |
7
| – | – | ﹤0.01% | 420 |
|
|
2024
Q3 | $3.26K | Hold |
7
| – | – | ﹤0.01% | 403 |
|
|
2024
Q2 | $3.28K | Hold |
7
| – | – | ﹤0.01% | 405 |
|
|
2024
Q1 | $2.93K | Sell |
7
-8
| -53% | -$3.38K | ﹤0.01% | 423 |
|
|
2023
Q4 | $6.1K | Buy |
15
+8
| +114% | +$2.96K | ﹤0.01% | 398 |
|
|
2023
Q3 | $2.43K | Hold |
7
| – | – | ﹤0.01% | 420 |
|
|
2023
Q2 | $2.46K | Hold |
7
| – | – | ﹤0.01% | 443 |
|
|
2023
Q1 | $2.21K | Hold |
7
| – | – | ﹤0.01% | 463 |
|
|
2022
Q4 | $2.02K | Sell |
7
-21
| -75% | -$6.4K | ﹤0.01% | 434 |
|
|
2022
Q3 | $8.11K | Hold |
28
| – | – | ﹤0.01% | 362 |
|
|
2022
Q2 | $7.89K | Hold |
28
| – | – | ﹤0.01% | 383 |
|
|
2022
Q1 | $7.31K | Buy |
28
+7
| +33% | +$1.66K | ﹤0.01% | 388 |
|
|
2021
Q4 | $4.61K | Hold |
21
| – | – | ﹤0.01% | 438 |
|
|
2021
Q3 | $3.81K | Hold |
21
| – | – | ﹤0.01% | 447 |
|
|
2021
Q2 | $4.23K | Hold |
21
| – | – | ﹤0.01% | 446 |
|
|
2021
Q1 | $4.51K | Hold |
21
| – | – | ﹤0.01% | 392 |
|
|
2020
Q4 | $4.96K | Hold |
21
| – | – | ﹤0.01% | 371 |
|
|
2020
Q3 | $5.71K | Hold |
21
| – | – | ﹤0.01% | 347 |
|
|
2020
Q2 | $6.1K | Hold |
21
| – | – | ﹤0.01% | 355 |
|
|
2020
Q1 | $5K | Hold |
21
| – | – | ﹤0.01% | 364 |
|
|
2019
Q4 | $4.6K | Hold |
21
| – | – | ﹤0.01% | 410 |
|
|
2019
Q3 | $3.56K | Hold |
21
| – | – | ﹤0.01% | 407 |
|
|
2019
Q2 | $3.85K | Hold |
21
| – | – | ﹤0.01% | 401 |
|
|
2019
Q1 | $3.86K | Hold |
21
| – | – | ﹤0.01% | 403 |
|
|
2018
Q4 | $3.48K | Hold |
21
| – | – | ﹤0.01% | 405 |
|
|
2018
Q3 | $4.05K | Hold |
21
| – | – | ﹤0.01% | 403 |
|
|
2018
Q2 | $3.57K | Hold |
21
| – | – | ﹤0.01% | 422 |
|
|
2018
Q1 | $3.42K | Hold |
21
| – | – | ﹤0.01% | 394 |
|
|
2017
Q4 | $3.15K | Hold |
21
| – | – | ﹤0.01% | 411 |
|
|
2017
Q3 | $3.19K | Hold |
21
| – | – | ﹤0.01% | 412 |
|
|
2017
Q2 | $2.71K | Hold |
21
| – | – | ﹤0.01% | 433 |
|
|
2017
Q1 | $2.3K | Sell |
21
-20
| -49% | -$1.76K | ﹤0.01% | 437 |
|
|
2016
Q4 | $3.02K | Buy |
+41
| New | +$3.34K | ﹤0.01% | 450 |
|
Other funds holding VRTX
MLL
AP
West Paces Advisors's VRTX Position: Q3 2026 in Review
West Paces Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 12 shares worth $6.27K. The position accounts for ﹤0.01% of the portfolio, ranked #436.
West Paces Advisors first reported a position in VRTX in Q4 2016 and has held it in 36 quarters since. The position peaked at $8.11K in Q3 2022. 209 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- West Paces Advisors held 12 shares of Vertex Pharmaceuticals worth $6.27K as of Q3 2026.
- West Paces Advisors left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
- Vertex Pharmaceuticals made up ﹤0.01% of West Paces Advisors's portfolio in Q3 2026, its #436 holding.
- West Paces Advisors first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 36 quarters since.
- West Paces Advisors's Vertex Pharmaceuticals position peaked at $8.11K in Q3 2022.
- 209 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on West Paces Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.